Ibrutinib: a paradigm shift in management of CLL.

about

Current and emerging treatment options for hairy cell leukemia A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.

P2860

Q26796423-C7691CB5-8F0E-40C9-84A4-512FD2F3CA81 Q36965127-DE52631B-14CD-4AF2-93DE-91F047CAE258 Q48273854-CCE8EB64-D26F-478E-AEE4-0D1527B59FC9

P2860

Ibrutinib: a paradigm shift in management of CLL.

Item

http://www.wikidata.org/entity/Q36739295

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Ibrutinib: a paradigm shift in management of CLL.

@ast

Ibrutinib: a paradigm shift in management of CLL.

@en

type

Item

label

Ibrutinib: a paradigm shift in management of CLL.

@ast

Ibrutinib: a paradigm shift in management of CLL.

@en

prefLabel

Ibrutinib: a paradigm shift in management of CLL.

@ast

Ibrutinib: a paradigm shift in management of CLL.

@en

P1476

Ibrutinib: a paradigm shift in management of CLL.

@en

P2093

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Talha Badar

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

How will B-cell-receptor-targeted therapies change future CLL therapy?

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Cancer statistics, 2014

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.

P304

705-717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474086.2014.977862

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William G Wierda

Susan O'Brien

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268230783

http://www.w3.org/2001/XMLSchema#string

P698

25387837

http://www.w3.org/2001/XMLSchema#string

P932

4811630

http://www.w3.org/2001/XMLSchema#string

Ibrutinib: a paradigm shift in management of CLL.

about

P2860

P2860

Ibrutinib: a paradigm shift in management of CLL.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932